nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—CYP3A4—chronic kidney failure	0.707	1	CbGaD
Tasosartan—AGTR1—nephron—chronic kidney failure	0.015	0.141	CbGeAlD
Tasosartan—AGTR2—renal system—chronic kidney failure	0.0131	0.124	CbGeAlD
Tasosartan—AGTR2—cardiovascular system—chronic kidney failure	0.013	0.122	CbGeAlD
Tasosartan—AGTR2—kidney—chronic kidney failure	0.0127	0.12	CbGeAlD
Tasosartan—AGTR2—blood—chronic kidney failure	0.0103	0.0966	CbGeAlD
Tasosartan—AGTR1—artery—chronic kidney failure	0.00837	0.0787	CbGeAlD
Tasosartan—AGTR1—blood plasma—chronic kidney failure	0.00628	0.059	CbGeAlD
Tasosartan—CYP3A4—urine—chronic kidney failure	0.00442	0.0415	CbGeAlD
Tasosartan—AGTR1—nephron tubule—chronic kidney failure	0.00324	0.0304	CbGeAlD
Tasosartan—AGTR1—renal system—chronic kidney failure	0.00294	0.0277	CbGeAlD
Tasosartan—AGTR1—cardiovascular system—chronic kidney failure	0.00291	0.0273	CbGeAlD
Tasosartan—AGTR1—kidney—chronic kidney failure	0.00284	0.0268	CbGeAlD
Tasosartan—AGTR1—cortex of kidney—chronic kidney failure	0.00277	0.0261	CbGeAlD
Tasosartan—CYP3A4—blood plasma—chronic kidney failure	0.0023	0.0217	CbGeAlD
Tasosartan—AGTR1—blood—chronic kidney failure	0.0023	0.0216	CbGeAlD
Tasosartan—Olmesartan—ABCC2—chronic kidney failure	0.00191	0.216	CrCbGaD
Tasosartan—Irbesartan—PTGS1—chronic kidney failure	0.00112	0.127	CrCbGaD
Tasosartan—Candesartan—PTGS1—chronic kidney failure	0.00112	0.127	CrCbGaD
Tasosartan—CYP3A4—renal system—chronic kidney failure	0.00108	0.0102	CbGeAlD
Tasosartan—CYP3A4—kidney—chronic kidney failure	0.00104	0.00983	CbGeAlD
Tasosartan—Losartan—ACE—chronic kidney failure	0.000901	0.102	CrCbGaD
Tasosartan—CYP3A4—digestive system—chronic kidney failure	0.000886	0.00834	CbGeAlD
Tasosartan—CYP3A4—blood—chronic kidney failure	0.000844	0.00794	CbGeAlD
Tasosartan—Valsartan—ALB—chronic kidney failure	0.000756	0.0856	CrCbGaD
Tasosartan—Losartan—CYP2C19—chronic kidney failure	0.000665	0.0754	CrCbGaD
Tasosartan—Irbesartan—CYP3A4—chronic kidney failure	0.000657	0.0744	CrCbGaD
Tasosartan—Candesartan—ABCB1—chronic kidney failure	0.000547	0.0619	CrCbGaD
Tasosartan—AGTR2—Signaling by GPCR—CRH—chronic kidney failure	0.000498	0.0028	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PIP5K1B—chronic kidney failure	0.000496	0.00278	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic kidney failure	0.000495	0.00278	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—F2—chronic kidney failure	0.000485	0.00272	CbGpPWpGaD
Tasosartan—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—chronic kidney failure	0.000483	0.00271	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—NPS—chronic kidney failure	0.000472	0.00265	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—DRD1—chronic kidney failure	0.000463	0.0026	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PGF—chronic kidney failure	0.000452	0.00253	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD1—chronic kidney failure	0.000451	0.00253	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—CYP1A1—chronic kidney failure	0.000451	0.00253	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HBEGF—chronic kidney failure	0.000443	0.00249	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—POMC—chronic kidney failure	0.000442	0.00248	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—chronic kidney failure	0.000442	0.00248	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP2C18—chronic kidney failure	0.000436	0.00245	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CCL2—chronic kidney failure	0.000433	0.00243	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—NPY—chronic kidney failure	0.000431	0.00242	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—AVP—chronic kidney failure	0.00043	0.00241	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PRKAG2—chronic kidney failure	0.000425	0.00238	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—AVP—chronic kidney failure	0.000424	0.00238	CbGpPWpGaD
Tasosartan—Losartan—CYP3A4—chronic kidney failure	0.000423	0.0479	CrCbGaD
Tasosartan—AGTR1—Allograft Rejection—IL1B—chronic kidney failure	0.000422	0.00237	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—OXT—chronic kidney failure	0.000415	0.00233	CbGpPWpGaD
Tasosartan—CYP3A4—Xenobiotics—CYP1A1—chronic kidney failure	0.000414	0.00233	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CRHR1—chronic kidney failure	0.000413	0.00232	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—EDN1—chronic kidney failure	0.000409	0.00229	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2B6—chronic kidney failure	0.000406	0.00228	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—EDN1—chronic kidney failure	0.000404	0.00227	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—COL4A3—chronic kidney failure	0.000403	0.00226	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP2B6—chronic kidney failure	0.000401	0.00225	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL5—chronic kidney failure	0.000401	0.00225	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic kidney failure	0.000398	0.00224	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—HBEGF—chronic kidney failure	0.000394	0.00221	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—NPS—chronic kidney failure	0.000394	0.00221	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD1—chronic kidney failure	0.000386	0.00217	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—chronic kidney failure	0.000385	0.00216	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CRHR1—chronic kidney failure	0.000384	0.00216	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—PTH—chronic kidney failure	0.000378	0.00212	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—AVP—chronic kidney failure	0.000376	0.00211	CbGpPWpGaD
Tasosartan—Losartan—ALB—chronic kidney failure	0.000369	0.0418	CrCbGaD
Tasosartan—AGTR2—Signaling Pathways—LRP2—chronic kidney failure	0.000368	0.00207	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic kidney failure	0.000366	0.00205	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCR5—chronic kidney failure	0.000361	0.00203	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—EDN1—chronic kidney failure	0.000358	0.00201	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—VEGFA—chronic kidney failure	0.000358	0.00201	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—chronic kidney failure	0.000358	0.00201	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CCL5—chronic kidney failure	0.000355	0.00199	CbGpPWpGaD
Tasosartan—Losartan—ABCB1—chronic kidney failure	0.000352	0.0399	CrCbGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—chronic kidney failure	0.000352	0.00198	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTH—chronic kidney failure	0.000351	0.00197	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—chronic kidney failure	0.000348	0.00195	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CYBB—chronic kidney failure	0.000342	0.00192	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AVP—chronic kidney failure	0.000341	0.00192	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2B6—chronic kidney failure	0.000329	0.00185	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TGFB1—chronic kidney failure	0.000328	0.00184	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—NPY—chronic kidney failure	0.000328	0.00184	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EDN1—chronic kidney failure	0.000325	0.00182	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FGF23—chronic kidney failure	0.000324	0.00182	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL5—chronic kidney failure	0.000322	0.00181	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CCR5—chronic kidney failure	0.00032	0.00179	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CRH—chronic kidney failure	0.000316	0.00178	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—OXT—chronic kidney failure	0.000316	0.00178	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—F2—chronic kidney failure	0.000314	0.00176	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—F2—chronic kidney failure	0.00031	0.00174	CbGpPWpGaD
Tasosartan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—chronic kidney failure	0.000309	0.00173	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TNF—chronic kidney failure	0.000307	0.00172	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NPY—chronic kidney failure	0.000305	0.00171	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—NPS—chronic kidney failure	0.0003	0.00168	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—chronic kidney failure	0.000294	0.00165	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—OXT—chronic kidney failure	0.000294	0.00165	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CRH—chronic kidney failure	0.000294	0.00165	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—DRD1—chronic kidney failure	0.000294	0.00165	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—chronic kidney failure	0.000292	0.00164	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCR5—chronic kidney failure	0.00029	0.00163	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—chronic kidney failure	0.000288	0.00162	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—chronic kidney failure	0.000286	0.0016	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AVP—chronic kidney failure	0.000285	0.0016	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—chronic kidney failure	0.000283	0.00159	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—POMC—chronic kidney failure	0.000282	0.00158	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NCF1—chronic kidney failure	0.000282	0.00158	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—chronic kidney failure	0.000281	0.00157	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NPS—chronic kidney failure	0.000279	0.00157	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL2—chronic kidney failure	0.000276	0.00155	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—F2—chronic kidney failure	0.000274	0.00154	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—DRD1—chronic kidney failure	0.000274	0.00154	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic kidney failure	0.000271	0.00152	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—chronic kidney failure	0.000269	0.00151	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CYBA—chronic kidney failure	0.000265	0.00149	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—POMC—chronic kidney failure	0.00025	0.0014	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—F2—chronic kidney failure	0.000249	0.0014	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—chronic kidney failure	0.000248	0.00139	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—chronic kidney failure	0.000242	0.00136	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CAT—chronic kidney failure	0.000238	0.00133	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—chronic kidney failure	0.000237	0.00133	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CRHR1—chronic kidney failure	0.000233	0.00131	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HBEGF—chronic kidney failure	0.000233	0.00131	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—POMC—chronic kidney failure	0.000227	0.00127	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL2—chronic kidney failure	0.000222	0.00125	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—AVP—chronic kidney failure	0.000217	0.00122	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—chronic kidney failure	0.000216	0.00121	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PTH—chronic kidney failure	0.000213	0.0012	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP1A1—chronic kidney failure	0.000213	0.00119	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CRHR1—chronic kidney failure	0.000212	0.00119	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2—chronic kidney failure	0.000208	0.00117	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—EDN1—chronic kidney failure	0.000206	0.00116	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL5—chronic kidney failure	0.000205	0.00115	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AVP—chronic kidney failure	0.000202	0.00113	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PTH—chronic kidney failure	0.000194	0.00109	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EDN1—chronic kidney failure	0.000192	0.00108	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL5—chronic kidney failure	0.00019	0.00107	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—chronic kidney failure	0.000189	0.00106	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LPL—chronic kidney failure	0.000186	0.00104	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—NPY—chronic kidney failure	0.000185	0.00104	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—chronic kidney failure	0.000185	0.00104	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCR5—chronic kidney failure	0.000184	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CRH—chronic kidney failure	0.000179	0.001	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—OXT—chronic kidney failure	0.000179	0.001	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—COL4A5—chronic kidney failure	0.000178	0.000997	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NGF—chronic kidney failure	0.000176	0.00099	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP2B6—chronic kidney failure	0.000175	0.000982	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP2B6—chronic kidney failure	0.000173	0.000968	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic kidney failure	0.000172	0.000965	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCR5—chronic kidney failure	0.000172	0.000963	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic kidney failure	0.00017	0.000953	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—NPS—chronic kidney failure	0.000169	0.000951	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—NPY—chronic kidney failure	0.000168	0.000944	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—DRD1—chronic kidney failure	0.000166	0.000933	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TFDP2—chronic kidney failure	0.000165	0.000927	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CRH—chronic kidney failure	0.000162	0.000911	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—OXT—chronic kidney failure	0.000162	0.000911	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PIP5K1B—chronic kidney failure	0.000162	0.000907	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—F2—chronic kidney failure	0.000158	0.000888	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—NPS—chronic kidney failure	0.000154	0.000864	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP2C18—chronic kidney failure	0.000152	0.000851	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—DRD1—chronic kidney failure	0.000151	0.000847	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP2C18—chronic kidney failure	0.00015	0.00084	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PGF—chronic kidney failure	0.000147	0.000826	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—F2—chronic kidney failure	0.000147	0.000826	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—POMC—chronic kidney failure	0.000144	0.000809	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL2—chronic kidney failure	0.000141	0.000791	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic kidney failure	0.000139	0.000783	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IRS1—chronic kidney failure	0.000139	0.000781	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PRKAG2—chronic kidney failure	0.000138	0.000776	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—chronic kidney failure	0.000136	0.000766	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—POMC—chronic kidney failure	0.000134	0.000752	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—COL4A3—chronic kidney failure	0.000131	0.000736	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL2—chronic kidney failure	0.000131	0.000736	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF1—chronic kidney failure	0.000129	0.000724	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—HBEGF—chronic kidney failure	0.000128	0.00072	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—chronic kidney failure	0.000128	0.00072	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP2C19—chronic kidney failure	0.000126	0.000705	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CRHR1—chronic kidney failure	0.000125	0.000702	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP2C19—chronic kidney failure	0.000124	0.000696	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AVP—chronic kidney failure	0.000123	0.000688	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SERPINE1—chronic kidney failure	0.000122	0.000687	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—KRAS—chronic kidney failure	0.000121	0.00068	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LRP2—chronic kidney failure	0.00012	0.000673	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOS3—chronic kidney failure	0.000117	0.000656	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—EDN1—chronic kidney failure	0.000117	0.000654	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CCL5—chronic kidney failure	0.000116	0.000649	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—PTGS1—chronic kidney failure	0.000115	0.000645	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTH—chronic kidney failure	0.000114	0.000642	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CYBB—chronic kidney failure	0.000112	0.000626	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AVP—chronic kidney failure	0.000111	0.000624	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic kidney failure	0.000111	0.000623	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RELA—chronic kidney failure	0.00011	0.000618	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EDN1—chronic kidney failure	0.000106	0.000594	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FGF23—chronic kidney failure	0.000106	0.000593	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL5—chronic kidney failure	0.000105	0.000589	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CCR5—chronic kidney failure	0.000104	0.000585	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—chronic kidney failure	0.000104	0.000584	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NPY—chronic kidney failure	9.94e-05	0.000558	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6—chronic kidney failure	9.86e-05	0.000553	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—OXT—chronic kidney failure	9.59e-05	0.000538	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CRH—chronic kidney failure	9.59e-05	0.000538	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCR5—chronic kidney failure	9.46e-05	0.000531	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NFKB1—chronic kidney failure	9.28e-05	0.000521	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NCF1—chronic kidney failure	9.18e-05	0.000515	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NPS—chronic kidney failure	9.09e-05	0.00051	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—F2—chronic kidney failure	8.94e-05	0.000502	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—DRD1—chronic kidney failure	8.92e-05	0.0005	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CYBA—chronic kidney failure	8.64e-05	0.000485	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—VEGFA—chronic kidney failure	8.42e-05	0.000473	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—POMC—chronic kidney failure	8.14e-05	0.000457	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—F2—chronic kidney failure	8.12e-05	0.000456	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TGFB1—chronic kidney failure	7.73e-05	0.000434	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HBEGF—chronic kidney failure	7.58e-05	0.000425	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1A1—chronic kidney failure	7.41e-05	0.000416	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—POMC—chronic kidney failure	7.39e-05	0.000415	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1A1—chronic kidney failure	7.31e-05	0.00041	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL2—chronic kidney failure	7.24e-05	0.000406	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KRAS—chronic kidney failure	7.16e-05	0.000402	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AVP—chronic kidney failure	6.57e-05	0.000369	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EDN1—chronic kidney failure	6.25e-05	0.000351	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL5—chronic kidney failure	6.2e-05	0.000348	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LPL—chronic kidney failure	6.07e-05	0.00034	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6—chronic kidney failure	5.83e-05	0.000327	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NGF—chronic kidney failure	5.75e-05	0.000322	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCR5—chronic kidney failure	5.59e-05	0.000314	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—POMC—chronic kidney failure	5.52e-05	0.00031	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—FABP1—chronic kidney failure	5.21e-05	0.000292	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AGXT—chronic kidney failure	4.94e-05	0.000277	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GATM—chronic kidney failure	4.94e-05	0.000277	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—F2—chronic kidney failure	4.8e-05	0.000269	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IRS1—chronic kidney failure	4.54e-05	0.000255	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ACAT1—chronic kidney failure	4.52e-05	0.000253	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—POMC—chronic kidney failure	4.37e-05	0.000245	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL2—chronic kidney failure	4.27e-05	0.00024	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1—chronic kidney failure	4.2e-05	0.000236	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MLXIPL—chronic kidney failure	4.2e-05	0.000236	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SERPINE1—chronic kidney failure	3.99e-05	0.000224	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—KRAS—chronic kidney failure	3.95e-05	0.000222	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SLC22A2—chronic kidney failure	3.84e-05	0.000216	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOS3—chronic kidney failure	3.81e-05	0.000214	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RELA—chronic kidney failure	3.59e-05	0.000201	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCG1—chronic kidney failure	3.57e-05	0.0002	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PIP5K1B—chronic kidney failure	3.49e-05	0.000196	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ARG2—chronic kidney failure	3.42e-05	0.000192	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LCAT—chronic kidney failure	3.36e-05	0.000188	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6—chronic kidney failure	3.21e-05	0.00018	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—DDC—chronic kidney failure	3.08e-05	0.000173	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NFKB1—chronic kidney failure	3.02e-05	0.00017	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PRKD1—chronic kidney failure	2.99e-05	0.000168	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PRKAG2—chronic kidney failure	2.99e-05	0.000168	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP2B6—chronic kidney failure	2.99e-05	0.000168	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SREBF2—chronic kidney failure	2.8e-05	0.000157	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VEGFA—chronic kidney failure	2.74e-05	0.000154	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GCKR—chronic kidney failure	2.71e-05	0.000152	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCC3—chronic kidney failure	2.71e-05	0.000152	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LPIN1—chronic kidney failure	2.65e-05	0.000149	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LRP2—chronic kidney failure	2.59e-05	0.000146	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP2C18—chronic kidney failure	2.59e-05	0.000146	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFB1—chronic kidney failure	2.52e-05	0.000141	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KRAS—chronic kidney failure	2.33e-05	0.000131	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CPT1A—chronic kidney failure	2.21e-05	0.000124	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LIPC—chronic kidney failure	2.15e-05	0.000121	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP2C19—chronic kidney failure	2.15e-05	0.000121	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SCARB1—chronic kidney failure	1.99e-05	0.000111	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS1—chronic kidney failure	1.97e-05	0.00011	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SREBF1—chronic kidney failure	1.93e-05	0.000108	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6—chronic kidney failure	1.9e-05	0.000107	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HMGCR—chronic kidney failure	1.88e-05	0.000105	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—FASN—chronic kidney failure	1.84e-05	0.000103	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCA1—chronic kidney failure	1.67e-05	9.38e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CAT—chronic kidney failure	1.42e-05	7.94e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCB1—chronic kidney failure	1.38e-05	7.73e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—LPL—chronic kidney failure	1.31e-05	7.36e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1A1—chronic kidney failure	1.27e-05	7.11e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MTHFR—chronic kidney failure	1.18e-05	6.63e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PPARA—chronic kidney failure	1.16e-05	6.5e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—POMC—chronic kidney failure	9.45e-06	5.3e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALB—chronic kidney failure	8.61e-06	4.83e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NOS3—chronic kidney failure	8.24e-06	4.62e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—chronic kidney failure	7.53e-06	4.23e-05	CbGpPWpGaD
